Mirum Pharmaceuticals, Inc. 8-K/A

What Happened
Mirum Pharmaceuticals (MIRM) filed an amendment to its Form 8-K on April 8, 2026 to provide financial information related to its acquisition of Bluejay Therapeutics, Inc. The amendment includes the audited financial statements of Bluejay as of and for the year ended December 31, 2025 and unaudited pro forma condensed combined financial information for Mirum giving effect to the Acquisition and the PIPE. The filing was signed by CEO Christopher Peetz.

Key Details

• Filed under Item 9.01 (Financial Statements and Exhibits) on April 8, 2026.
• Exhibit 99.1: Audited financial statements of Bluejay Therapeutics, Inc. for the year ended December 31, 2025.
• Exhibit 99.2: Unaudited pro forma condensed combined balance sheet as of December 31, 2025, and pro forma condensed combined statements of operations for the year ended December 31, 2025, giving effect to the Acquisition and the PIPE, plus related notes.
• Exhibit 23.1: Consent of Deloitte & Touche LLP, independent auditors; Exhibit 104: iXBRL cover page.

Why It Matters
This filing provides investors with the historical financials of the acquired company (Bluejay) and pro forma combined results that show how the Acquisition and the PIPE affect Mirum’s balance sheet and operations as of year-end 2025. Those documents are important for assessing the transaction’s immediate accounting impact, potential dilution from the PIPE, and how the combined entity’s financial position and results would have looked on a pro forma basis.